NCT02842931 - R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

February 29, 2020

Study Completion Date

February 28, 2023

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG

R-DA-EPOCH-21

R-DA-EPOCH-21 treatment without auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI

DRUG

R-DA-EPOCH-21 + auto-SCT

R-DA-EPOCH-21 treatment with auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI

DRUG

R-mNHL-BFM-90

R-mNHL-BFM-90 without auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI

DRUG

R-mNHL-BFM-90 + auto-SCT

R-mNHL-BFM-90 with auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI

Trial Locations (1)

RECRUITING

National Research Center for Hematology, Moscow